Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fechukwu Akhmedzhanov"'
Autor:
Heather Lin, Selvi Thirumurthi, Abdulrazzak Zarifa, Juan Ibarra Rovira, Raghunandan Vikram, Bulent Yilmaz, Fechukwu Akhmedzhanov, Melissa Tagart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/a79d47e46ff34b0f801cea1d0e45d06e
Autor:
Shannon N. Westin, Siqing Fu, Apostolia Tsimberidou, Sarina Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L. Brink, Jing Gong, Cheuk Hong Leung, Heather Lin, David S. Hong, Shubham Pant, Brett Carter, Amir Jazaeri, David Gershenson, Anil K. Sood, Robert L. Coleman, Jatin Shah, Funda Meric-Bernstam, Aung Naing
Publikováno v:
Gynecologic oncology. 168
Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound which blocks Exportin-1 (XPO1). Our objective was to determine maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of selinexor and weekly paclita
Autor:
Jatin J. Shah, Funda Meric-Bernstam, Robert L. Coleman, David M. Gershenson, Fechukwu Akhmedzhanov, Shubham Pant, Heather Lin, Anil K. Sood, Shannon N. Westin, Bulent Yilmaz, Aung Naing, Cheuk Hong Leung, David S. Hong, Siqing Fu, Sarina Anne Piha-Paul, Amanda Lee Brink, Jing Gong, Lacey McQuinn, Amir A. Jazaeri, Apostolia Maria Tsimberidou
Publikováno v:
Journal of Clinical Oncology. 39:5565-5565
5565 Background: Selinexor is a first-in-class novel, oral potent selective inhibitor of nuclear export (SINE) which blocks Exportin-1 (XPO1) leading to nuclear accumulation and activation of tumor suppressor proteins and prevention of translation of
Autor:
Mingxuan Xu, Abdualrazzak Zarifa, Bettzy Stephen, Camilo Jimenez, Aung Naing, Apostolia Maria Tsimberidou, Vivek Subbiah, Jordi Rodon Anhert, Junsheng Ma, Mouhammed Amir Habra, Denái R. Milton, Fechukwu Akhmedzhanov, Siqing Fu
Publikováno v:
Cancers, Vol 12, Iss 2307, p 2307 (2020)
Cancers
Volume 12
Issue 8
Cancers
Volume 12
Issue 8
Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Syste
Autor:
Kathleen M. Schmeler, Fechukwu Akhmedzhanov, Amber Johnson, Bettzy Stephen, Alpa M. Nick, Shumei Kato, Yali Yang, Siqing Fu, Karen H. Lu, Shubham Pant, Sarina Anne Piha-Paul, Anil K. Sood, Funda Meric-Bernstam, Amir A. Jazaeri, Diane C. Bodurka, Aung Naing, Daniel D. Karp, Pamela T. Soliman, Vivek Subbiah, Jing Gong, Senait Fessahaye
Publikováno v:
Cancer Research. 80:CT163-CT163
Purpose: There is limited success with chemotherapeutic agents in women with advanced or recurrent endometrial cancer. Dysregulation of the PI3K/RAS signaling pathways in endometrial cancer have been well documented. However, responses with mTOR inhi
Autor:
Stephen G. Swisher, Linda Zhong, John V. Heymach, J. Jack Lee, Tito R. Mendoza, Ajay Sheshadri, Aung Naing, Abdulrazzak Zarifa, Jeff Lewis, Waree Rinsurongkawong, Fechukwu Akhmedzhanov, Mehmet Altan, Jianjun Zhang, Nathaniel R. Wilson, Vickie R. Shannon, Muhammad H. Arain, Felipe Soto
Publikováno v:
Journal of Clinical Oncology. 38:e15089-e15089
e15089 Background: Conventional treatments for advanced-stage non-small cell lung cancer (NSCLC) confer a progression-free survival of only about 6 months. Immune checkpoint inhibitors (ICIs) have become standard therapies in the management of advanc
Autor:
Kiran Motwani, Kenechukwu Chudy-Onwugaje, Osman Ali, Katherine Gheysens, Raymond K. Cross, Ryan Jackson, Grace E. Kim, Fechukwu Akhmedzhanov
Publikováno v:
Gastroenterology. 158:S-743
Autor:
Katherine Gheysens, Fechukwu Akhmedzhanov, Kiran Motwani, Kenechukwu Chudy-Onwugaje, Raymond K. Cross, Grace E. Kim, Ryan Jackson, Osman Ali
Publikováno v:
Gastroenterology. 158:S-652